Elizabeth A. Hughes

This paper develops a time-based drug screening platform to assess clinical utility by integrating pharmacokinetic-pharmacodynamic models and analyzing drug potency and kinetics in cancer cell lines.

This paper creates a large clinical dataset linking drug efficacy metrics to cancer outcomes and shows that exposure normalization improves the alignment between lab and clinical results.